Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

livisto int’l, s.l. - Преднизолон - таблетка - 25 mg/таблетка - котки, кучета

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

livisto int’l, s.l. - Преднизолон - таблетка - 5 mg/таблетка - котки, кучета

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

livisto int' l s.l. - Метронидазол - таблетка - 100 mg/таблетка - котки, кучета

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

livisto int' l s.l. - Метронидазол - таблетка - 250 mg/таблетка - котки, кучета

Umoja wa Ulaya - Kibulgaria - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Антинеопластични средства - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

fatro s.p.a. - Моксидектин - прах и разтворител за инжекционна суспензия - 100 mg/g - кучета

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

livisto int’l, s.l. - amoxicillin (as amoxicillin trihydreate); clavulanic acid (as potassium clavulanate) - таблетка - 500 mg; 125 mg/tablet - кучета

Bulgaria - Kibulgaria - БАБХ (Българска агенция по безопасност на храните)

fatro s.p.a. - lecirelin - инжекционен разтвор - 25 microgram/ml - говеда, зайци

Umoja wa Ulaya - Kibulgaria - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - Множествена миелома - Антинеопластични средства - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Umoja wa Ulaya - Kibulgaria - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.